What’s Ahead for 2018?

Drug Industry Daily
In this issue of Drug Industry Daily, we examine some of the FDA’s priorities for 2018 and what industry experts expect to happen. We already know the FDA’s priorities for 2018 will include ongoing efforts to reduce drug prices, speed approvals for generics, and increase patient engagement, according to FDA officials and expert observers. On the quality front, the agency will target data-integrity as part of its new ConOps initiative. The EMA, meanwhile, will be juggling its regulatory obligations with Brexit preparations and the transfer of its headquarters from London to Amsterdam.

To View This Article:


Subscribe To Drug Industry Daily